According to an article published in the July 30, 2015 online edition of JAMA Oncology, the presence of persistent human papillomavirus (HPV) type 16 DNA in oral rinses after treatment for HPV-related oropharyngeal cancer was rare but it appears to be associated with poor prognosis and therefore may have potential as a long-term tool for tumor surveillance.
HPV infection is responsible for the majority of oropharyngeal carcinomas in the United States. In 10 - 25% of all patients with…Continue
Added by Editorial Team on July 30, 2015 at 10:00am — No Comments
Atezolizumab (also known as MPDL3280A; Roche/Genentech), a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1), is poised to become a major bladder cancer therapy in the race for U.S. Food & Drug Administration (FDA) approval, following its promising performance in recent Phase II trials. This is the conclusion of research analysts working for the London-based…Continue
Added by Editorial Team on July 28, 2015 at 11:00am — No Comments
A new study points to the need for increased awareness of fertility preservation options for young patients with cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study found that factors such as gender, education, and insurance status may impact whether patients and their physicians have discussions and take…Continue
Added by Editorial Team on July 27, 2015 at 3:00am — No Comments
A new review published in the Cochrane Library, indicates that eradicating Helicobacter pylori bacterium— the main cause of stomach ulcers - with a short course of therapy comprising two commonly used medicines may help to reduce the risk of gastric cancer.
Stomach, or gastric, cancer is the third most common cause of death from cancer worldwide, and people who are infected with the Helicobacter pylori bacterium are more likely to develop the…Continue
Added by Editorial Team on July 22, 2015 at 11:30am — No Comments
Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, according to study results presented today at the ESMO …Continue
Added by Editorial Team on July 4, 2015 at 11:30am — No Comments